


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: November 19, 2007

Signature:

  
(Lynn L. Janulis)

(PATENT APPLICATION)

Atty Docket: 31280/42996

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U.S. Patent Application Serial No.:	)	
10/821,234	)	
	)	
Applicants: Labat et al.	)	Art Unit: 1634
	)	
Filed: April 7, 2004	)	Examiner: Jeanine Anne Goldberg
	)	
Title: Methods and Diagnosis for the	)	
Treatment of Preeclampsia	)	
	)	
Customer No. : 04743	)	

**RESPONSE TO RESTRICTION REQUIREMENT**


MS Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement mailed on March 3, 2006 in the above-identified patent application, Applicants hereby elect without traverse the claims of Group II as they are drawn to the polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1552 for prosecution in the application.

Dated: November 19, 2007

Respectfully submitted,

By   
Lynn L. Janulis, Ph.D.

Registration No.: 53,066

Agent for Applicants

MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300